Skip to main content
Johnnie Orozco, MD, Oncology, Seattle, WA

JohnnieJoseOrozcoMD

Oncology Seattle, WA

Hematologic Oncology

Associate Professor

Dr. Orozco is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Orozco's full profile

Already have an account?

  • Office

    1100 Fairview Ave N, D3-190
    Seattle, WA 98109

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2009 - 2012
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 2006
  • University of Washington
    University of WashingtonPhD, Bioengineering, 1999 - 2004

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2008 - Present
  • WA State Medical License
    WA State Medical License 2009 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...  
    Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica

Abstracts/Posters

  • Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
    Johnnie Orozco, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
    Johnnie Orozco, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • $3.4 Million Grant to Find Safer, More Effective Leukemia Treatments
    $3.4 Million Grant to Find Safer, More Effective Leukemia TreatmentsJuly 27th, 2020

Professional Memberships